Get the Stockscreener App
41.12
1.91%
-0.80
After Hours:
36.00
-5.12
-12.45%
Xenon Pharmaceuticals Inc stock is traded at $41.12, with a volume of 1.11M.
It is down -1.91% in the last 24 hours and up +3.81% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$41.92
Open:
$41.6
24h Volume:
1.11M
Relative Volume:
1.34
Market Cap:
$3.17B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-15.01
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
-1.84%
1M Performance:
+3.81%
6M Performance:
+7.42%
1Y Performance:
-1.37%
1-Day Range:
$40.13
$41.70
1-Week Range:
$40.13
$42.96
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
41.12 | 3.23B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlight - GuruFocus
Xenon Pharmaceuticals Inc (XENE) Q3 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo! Finance Canada
Xenon Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
Earnings call transcript: Xenon Pharmaceuticals Q3 2025 sees steady cash reserves - Investing.com
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q3 EPS $-1.15, vs. FactSet Est of $-1.15 - MarketScreener
XENE Financial Position Update: Cash Holdings Decline - GuruFocus
Xenon Reports Q3 2025 Financial Results and Progress - TipRanks
Xenon Pharmaceuticals: Q3 Earnings Snapshot - KVUE
Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Xenon Pharmaceuticals Keeps R&D Rolling While Analysts Stay Bullish - Finimize
Xenon Reports Third Quarter 2025 Financial Results & Business Update - The Manila Times
Xenon Pharmaceuticals Q3 net loss beats expectations - MarketScreener
When is the best time to exit Xenon Pharmaceuticals Inc.Portfolio Update Summary & Target Return Focused Stock Picks - newser.com
Will Xenon Pharmaceuticals Inc. price bounce be sustainableInsider Buying & Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Xenon Pharmaceuticals Inc.2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Can Xenon Pharmaceuticals Inc. stock deliver sustainable ROEWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
How strong is Xenon Pharmaceuticals Inc. stock revenue growthLong Setup & Safe Capital Growth Stock Tips - newser.com
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Why Xenon Pharmaceuticals Inc. stock is trending among retail tradersQuarterly Performance Summary & Reliable Price Breakout Signals - newser.com
Why Xenon Pharmaceuticals Inc. stock could outperform in 20252025 Trade Ideas & Daily Profit Focused Stock Screening - newser.com
Using Ichimoku Cloud for Xenon Pharmaceuticals Inc. technicalsIndex Update & Fast Momentum Entry Tips - newser.com
Tools to monitor Xenon Pharmaceuticals Inc. recovery probabilityQuarterly Profit Review & Real-Time Buy Signal Alerts - newser.com
Technical signs of recovery in Xenon Pharmaceuticals Inc.Recession Risk & Weekly High Potential Alerts - newser.com
What valuation multiples suggest for Xenon Pharmaceuticals Inc. stock - newser.com
State of New Jersey Common Pension Fund D Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. $XENE Position Trimmed by Jennison Associates LLC - MarketBeat
Chart overlay techniques for tracking Xenon Pharmaceuticals Inc.July 2025 Short Interest & AI Powered Market Entry Strategies - newser.com
Will Xenon Pharmaceuticals Inc. stock continue dividend increasesJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Traders Buy High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Intraday pattern recognizer results for Xenon Pharmaceuticals Inc.July 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Xenon Pharmaceuticals Inc. (XENE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Xenon Pharmaceuticals Inc. (XENE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday - MarketBeat
Xenon Pharmaceuticals’ XEN1101: A Promising Epilepsy Treatment in the Making - The Globe and Mail
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):